Trial Profile
Phase II study of regorafenib with dose adjustment and pharmacokinetic analysis in advanced colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 18 Feb 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.